-
MOASC is pleased to acknowledge Santosh Kesari, MD,PhD, as the MOASC July Researcher of the Month for his ongoing cancer research in neurooncology! Dr. Kesari is Director of Neuro-Oncology; Chair and Professor, Department of Translational Neurosciences and Research Medical Director at Research Clinical Institute, Providence Southern California. Watch the interview with Dr. Kesari here! https://www.youtube.com/watch?v=vtTCWiuYkMI
|
|
MOASC has a new address! Please make changes to your directory. |
|
Mail and Letters
MOASC
Po Box 400606
Hesperia, CA 92340
|
|
Packages and Magazines
MOASC
17240 Olive Street, Box 400606
Hesperia, CA 92340
|
|
-
TOMORROW! MOASC’s Lung Cancer Webinar Series, July 27, 2022, 6:00pm-PDT, will discuss Adjuvant Therapy in Non-Small Cell Lung Cancer. This event is part of MOASC’s virtual Lung Webinar Series. This will be a great opportunity to learn from key opinion leaders along with engaging in professional exchange of ideas.
|
|
-
MOASC presents FOTIVDA®(tivozanib) Efficacy, Safety, and Use for Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma (rrRCC) Following 2 or More Prior Systemic Therapies, Thursday, August 25, 2022, 5:30pm-PDT.
|
|
-
MOASC, in partnership with the UCI Hematology/Oncology Fellowship Program and Faculty, has organized a LIVE learning symposia, Spotlight On Clinical Oncology, Saturday, August 27, 2022, 1:00pm to 7:00pm-PDT. This program will cover timely updates in clinical practice, research & development and technology & drug advancements in the field of medical oncology. Oncology experts will discuss innovations in the diagnosis and management of complex oncology issues, including highlights from the Annual ASCO meeting. This Activity is approved for AMA PRA Category 1 Credits™.
|
|
-
Register for ANCO’s ASCO22 Highlights, August 27.
|
|
-
Los Angeles County to impose new indoor mask rules this week, Thursday, as data show the hyper-infectious BA.5 omicron subvariant is pushing coronavirus case counts higher and sending increasing numbers of people to the hospital.
|
|
-
DHCS sunsets the Proposition 56 funded Medi-Cal Value-Based Payments program, effective July 1, 2022. The program incentivized providers for meeting specific measures and benchmarks that improve the quality of care provided to Medi-Cal beneficiaries.
|
|
-
Implementation of the Cigna policy to require the submission of medical records with all Evaluation and Management claims with CPT 99212-99215 and modifier 25 when a minor procedure is billed, will be delayed.
|
|
- Exhibit Opportunity! On behalf of Dr. Ezra Cohen and Liza Blumenfeld, you are invited to exhibit at the Multidisciplinary Head and Neck Cancer Care Conference and 5th New Horizons in Immunotherapy conference, September 22-23, 2022 to be held at the San Diego Marriott Marquis.
|
|
-
Effective July 1, 2022, the sequestration cuts have reverted to 2%, the rate that was in effect prior to the public health emergency. On April 1, 2022, CMS began to phase back in previously suspended sequestration cuts, with a 1% cut taking effect April 1.
-
CMS has announced a new voluntary, value-based oncology payment model aimed at reducing cancer care costs and improving patient outcomes, and the model will be studied from July 2023 to June 2028. Practices, Medicare Advantage plans and Medicaid plans are encouraged to apply to join the Enhancing Oncology Model, which involves monthly payments for enhanced cancer care services, performance-based retrospective payments and additional payments for offering new services to dual-eligible beneficiaries.
|
|
-
The FDA Division of Hematologic Malignancies is looking for 3-4 community oncologists to be panelists for their virtual mini symposium, “Acute Myeloid Leukemia Treatment in the Community Oncology Setting.” They are tentatively planning the session to take place November 16, 2022, 1-4 pm EST. The FDA wants to engage with community oncologists across the country to address 1) opportunities and challenges with treatment of AML in the community oncology setting, 2) new AML approvals and changes in practice, and 3) opportunities for engagement with FDA. They want to hear from community oncologists about issues in trial design from their perspective and clinically meaningful endpoints. They are interested to hear how much people look at the drug labels, how FDA can make accessing information easier for community providers to identify benefit/risk, and also other practice considerations like referral to tertiary care. If you or a colleague are interested, please email the FDA’s Ashley Woods at Ashley.Woods@fda.hhs.gov.
-
Numerous opportunities are now open, supporting a wide range of research initiatives designed to provide insight into every aspect of oncology to professionals in all stages of their careers with funding from the Conquer Cancer Grants & Awards program.
|
|
-
Provide Your Feedback on Clinical Practice Guidelines for ASCO Study. Medical and clinical oncologists practicing in the United States are asked to give feedback on their perceptions of clinical practice guidelines. There are two current opportunities to contribute your perspective: respond to a 5-minute survey and/or sign up for a 45 minute interview to receive a $50 gift card for your time.
|
|
-
Health insurance providers and self-insured employer plans must disclose how much they pay for nearly every health care service and item with the exception of prescription drugs taken at home, per rule that took effect Friday.
|
|
-
In June 2022, the Supreme Court ruled that the Department of Health and Human Services (HHS) may not vary reimbursement rates for drugs and biologicals among groups of hospitals without conducting a survey of hospital acquisition costs. Given the timing of the Supreme Court decision, CMS was unable to adjust its proposed payment rates and budget neutrality calculations to account for the decision before issuing its proposal. As a result, while CMS is proposing a reimbursement rate of average sales price (ASP) minus 22.5% for drugs and biologicals acquired through the 340B drug pricing program, the agency anticipates finalizing a reimbursement rate of ASP plus 6% for such drugs and biologicals in the 2023 final rule. While changes to the OPPS payment rates and the conversion factor that reflect the Supreme Court decision are anticipated to be reflected in the language of the final rule, in the interim, CMS will make relevant impact tables and other supporting data associated with the alternative policy available.
|
|
-
Join Incyte Corporation for a live webinar about myeloproliferative neoplasms (MPN). Choose from the two opportunities below:
|
|
-
AstraZeneca and City of Hope cordially invites you to their webinar on “HealthCare Disparities: Impacting the Barriers to Lung Cancer Screening at Federally Qualified Healthcare Centers”, on Wednesday, July 27 at 12:00pm-PST.
|
|
-
6th Annual School of Nursing Oncology™ Conference, July 29-30, 2022, Marriott Marquis San Diego Marina Hotel, San Diego, CA. MOASC members discounted registration.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
